2026-01-28 - Analysis Report
**Company Overview**
Novo Nordisk is a Danish multinational pharmaceutical company specializing in diabetes care and haemophilia treatment.

**Return Rate Comparison**

* Ticker: NVO
* Cumulative return of review stock: 97.22%
* Cumulative return of comparison stock (S&P 500, VOO): 128.51%
* Divergence (max: 298.60, min: -79.80, current: -26.90, relative divergence: 14.00%)

**Alpha, Beta Analysis**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|--------|
| 2016-2018  | 4.0% | 18.2% | -5.0% | 0.8 | 102.4B |
| 2017-2019  | 54.0% | 14.1% | 29.0% | 0.6 | 128.6B |
| 2018-2020  | 23.0% | 23.6% | -1.0% | 0.6 | 155.2B |
| 2019-2021  | 118.0% | 23.6% | 54.0% | 0.6 | 248.8B |
| 2020-2022  | 116.0% | 23.6% | 111.0% | 0.6 | 300.7B |
| 2021-2023  | 208.0% | 19.9% | 190.0% | 0.5 | 459.7B |
| 2022-2024  | 78.0% | 41.1% | 48.0% | 0.5 | 382.2B |
| 2023-2025  | -98.0% | 67.0% | -174.0% | 0.7 | 226.1B |

**Recent Stock Price Fluctuations**

* Close: $62.89
* 5-day SMA: $62.14
* 20-day SMA: $57.96
* 60-day SMA: $51.65

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence**

* Market Risk Indicator (MRI): 0.70
* RSI: 66.32
* PPO: 0.45
* Buy (Cash 0%) Risk Level: Medium (MRI 0.70)
* Recent (20 days) relative divergence change: 1.30 (+): improving
* 7-day Rank change: 1 (+): rank up
* 7-day Dynamic Expected Return change: 655.50 (+): improving
* Expected Return (%): 918.70%

**Recent News & Significant Events**

* 2026-01-26: Prediction: This Healthcare Stock Could Soar by 40% in 2026 - The Motley Fool
* 2026-01-25: Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog - Seeking Alpha
* 2026-01-27: Novo Nordisk Regains Spotlight with New Oral Formulation, Stock May Have 40% Upside Potential - NAI500
* 2026-01-27: Novo Nordisk A/S $NVO Shares Bought by Markel Group Inc. - MarketBeat
* 2026-01-27: 1 Pharmaceutical Stock Set to Rebound in 2026 - The Globe and Mail
* 2026-01-23: Oral Wegovy Is Off To An Astronomical Launch. Will It Save Novo Nordisk Stock? - Investor's Business Daily

**Analyst Opinions**
 Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.38 (~Buy)
- Opinions: 11
- Target Price (avg/high/low): 60.01 / 75.99 / 43.19

**Comprehensive Analysis**
Based on the provided data, Novo Nordisk's stock price has shown significant fluctuations in recent years. The cumulative return of review stock is 97.22%, while the comparison stock (S&P 500, VOO) has a cumulative return of 128.51%, resulting in a divergence of -26.90. The Alpha, Beta analysis shows varying returns in different year ranges, with some years having high returns and others experiencing significant losses. The recent news highlights the potential for Novo Nordisk's stock to rise due to the successful launch of its Oral Wegovy and the potential for a 40% upside in 2026. The Analyst Consensus suggests a buy recommendation with a target price of 60.01, indicating a positive outlook for the company.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.